I'd agree with Dew on this point as well. Waiting to push development once final guidance has been given would put them at a significant disadvantage.
Others would continue development with the rough guidelines and be much further ahead in the regulatory process than Momenta. Falling behind really isn't an option.
They should be pushing the programs they can conduct now, without incurring undue regulatory risk.
Well let me clarify a bit. I'm fine with an initial push on FOBs, but I don't see how that can be all that expensive.
But assume for example that FOB's are not going to be fully substitutable and clinical trials are going to be required. That would both increase the cost of development and reduce the ultimate reward. That would certainly change which FOBs are worth developing.
Peter
(Edit - I now see the comment by Shea that they will spend the money on FOB's, and I have no reason not to take him at his word).
Market Data 
Markets 
AI
